Open | $168.330 |
Close | $168.500 |
Volume / Avg. | 154.842K / 306.570K |
Day Range | 168.330 - 170.780 |
52 Wk Range | 132.950 - 272.490 |
Market Cap | $17.626B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 55 |
Short Interest | % |
Days to Cover | 6.05 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of BeiGene (NASDAQ: BGNE) through any online brokerage.
Other companies in BeiGene’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for BeiGene (NASDAQ: BGNE) was reported by Guggenheim on Tuesday, February 27, 2024. The analyst firm set a price target for 345.00 expecting BGNE to rise to within 12 months (a possible 104.40% upside). 13 analyst firms have reported ratings in the last year.
The stock price for BeiGene (NASDAQ: BGNE) is $168.79 last updated March 18, 2024 at 9:30 AM EDT.
There are no upcoming dividends for BeiGene.
BeiGene’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for BeiGene.
BeiGene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.